Article
BACE1 as an early biomarker and its relevance to risk factors for Alzheimer’s disease
22 Jul 2025
Abstract excerpt
While the β-secretase BACE1 is responsible for the rate-limiting initial step to generate amyloid-β (Aβ) peptides, BACE1 inhibitor clinical trials have been halted due to a lack of efficacy and/or safety concerns at symptomatic/prodromal stages of Alzheimer's disease (AD). These trials were often targeted at high levels of BACE1 inhibition (>70 %) and ended up with signs of mild cognitive worsening instead of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
